Brookline Capital Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $17
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
Y-mAbs Therapeutics Initiated With a Buy at Brookline on Danyelza Potential
Brookline Capital Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $17
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 28% Plummet
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Institutional Investors Lost 13% Last Week but Have Benefitted From Longer-term Gains
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21
Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)
Y-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy Rating
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Y-Mabs Therapeutics Faces Uncertain Growth Amid Declining Danyelza Sales and Market Challenges
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript Summary
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript